Lundbeck’s Phase III MASCOT trial enrolled 401 participants with clinically probable or established multiple system atrophy, and the first public look at that population lands this week as a late-breaking oral presentation at MDS 2026 in Seoul. That baseline readout matters because the full efficacy results, comparing amlenetug against placebo over 72 weeks, are not expected until Q3 2027. What the field gets now is a window into who is actually in the trial: both MSA-C and MSA-P subtypes are represented, suggesting Lundbeck built for breadth rather than restricting enrollment to the more homogeneous population that sometimes tempts sponsors trying to sharpen a signal.
The stakes are real. Amlenetug received FDA Fast Track Designation in February 2025 after the Phase 2 AMULET trial showed a 19% slowing of decline that did not reach statistical significance. No drug has been approved to modify MSA’s underlying progression; droxidopa addresses one common symptom, neurogenic orthostatic hypotension, but not the disease itself. Lundbeck is also presenting research this week on the modified UMSARS Part I as a validated functional endpoint and on a CSF alpha-synuclein assay designed to distinguish MSA from Parkinson’s disease, both of which matter for how any future regulatory submission gets structured.
A US observational database study being presented alongside the clinical work found significantly higher healthcare costs and resource utilization in MSA patients compared with people with Parkinson’s disease. That framing is deliberate: payers will eventually need to weigh treatment costs against the current care burden, and building that evidentiary record now, years before a potential approval, is standard preparation for a difficult reimbursement conversation.
The second thread at MDS is earlier-stage: Phase Ib data for Lu AF28996, an oral D1-like/D2-like dopamine receptor agonist tested over 18 weeks in patients with advanced Parkinson’s disease experiencing poorly controlled motor fluctuations. Preclinical data in an MPTP-macaque model, presented alongside it, explore the dose-response relationship between motor benefit and dyskinesia risk. Both compounds remain investigational with no regulatory approval, and the Parkinson’s work is exploratory. The number to track between now and late 2026 is whether Lundbeck advances Lu AF28996 into a larger, controlled Parkinson’s trial on the strength of this Phase Ib safety and tolerability read.
AF28996: the facts in one place
- Also written: Lu AF28996
- Sponsor: H. Lundbeck A/S
- Mechanism: small molecule dual agonist of D1/D3 and D2/D5 dopamine receptors
- Indication studied: Parkinson’s disease
- Phase: Phase II
- Registry identifier: NCT07514858
- Current status: Phase II clinical development (DARE2 trial) evaluating efficacy, safety, and tolerability.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
